Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Source: SeekingAlpha
2025-03-29 16:30:00 ET
Summary
- Harrow's stock is down 17% since my last analysis and "Sell" recommendation.
- Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex reimbursement challenges and tough competition.
- Valuation models suggest Harrow is fairly valued if it achieves 20% revenue growth and 15% FCF margins, though these are lofty expectations.
- I upgrade Harrow to "Hold" due to its solid earnings and more reasonable valuation, but remain cautious about its complex business structure and high growth targets.
Introduction
Harrow, Inc. ( HROW ) stock is down another 17% since my “ Sell ” recommendation in December....
Read the full article on Seeking Alpha
For further details see:
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Harrow Health Inc.
NASDAQ: HROW
HROW Trading
-4.58% G/L:
$33.77 Last:
418,081 Volume:
$35.80 Open:
